Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

709
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
709
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

578
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
578
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

863
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and treatment strategies for airway involvement in relapsing polychondritis: a comprehensive review.

Frontiers in immunology·2026
Same author

A Risk Factor Atlas for Allergy-Related Airway Diseases: Evidence From Multi-Biobank Genetic Study.

Allergy, asthma & immunology research·2026
Same author

Research Progress in Traditional Chinese Medicine Intervention of Autophagy in the Treatment of Osteoporosis.

Journal of visualized experiments : JoVE·2026
Same author

[Using Xiaoqinglong Decoction to Treat Acute Exacerbation of Chronic Obstructive Pulmonary Disease Presenting External Cold and Internal Fluid Retention Syndrome: Observation of the Clinical Efficacy].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2025
Same author

Observational and Genetic Evidence Reveals the Effect of Serum Lipid Levels on COPD Risk.

International journal of chronic obstructive pulmonary disease·2025
Same author

Geniposide Suppresses Tumor Progression Through DUOX1-Mediated Ferroptosis in Hepatocellular Carcinoma.

The American journal of Chinese medicine·2025

Related Experiment Video

Updated: Jan 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Lipids, Lipid-Lowering Drug Target Genes, and COPD Risk: A Mendelian Randomization Study.

Guobing Jia1,2, Tao Guo1, Lei Liu3

  • 1School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|November 10, 2025
PubMed
Summary

This study genetically links lower low-density lipoprotein cholesterol (LDL-C) and specific genes (HMGCR, PCSK9) to reduced chronic obstructive pulmonary disease (COPD) risk. These findings suggest statins may protect against COPD through mechanisms beyond just lowering cholesterol.

Keywords:
COPDMendelian randomizationcausalitylipid-lowering drug target geneslipids

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Experiment Videos

Last Updated: Jan 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Area of Science:

  • Genetics
  • Pharmacology
  • Pulmonology

Background:

  • Statins may reduce chronic obstructive pulmonary disease (COPD) risk, but the mechanism is unclear.
  • The causal link between serum lipid levels and COPD risk requires further investigation.

Purpose of the Study:

  • To clarify the causal relationship between lipid levels and COPD risk.
  • To evaluate the impact of lipid-lowering drug target genes on COPD risk.

Main Methods:

  • Mendelian randomization (MR) analysis was employed.
  • Data were sourced from publicly available genome-wide association study databases.
  • Inverse variance weighted method and sensitivity analyses were utilized.

Main Results:

  • Lower low-density lipoprotein cholesterol (LDL-C) was causally associated with reduced COPD risk (OR=0.90).
  • Causal links between COPD risk reduction and lipid-lowering genes HMGCR (OR=0.63) and PCSK9 (OR=0.87) were identified.
  • A potential association with LPL was not supported by colocalization analysis.

Conclusions:

  • Serum LDL-C levels, HMGCR, and PCSK9 are genetically linked to a reduced risk of COPD.
  • Statins may offer protection against COPD independently of their lipid-lowering effects.
  • Further clinical studies are necessary to validate these genetic findings.